Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Open accessThe DOI matches its Crossref record; 69 of the 74 references it cites were found in a registry or an index.
Abstract
Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“| Loomba et al. | TVB-2640 | NAFLD + fibrosis | PDFF -4.8 % | ↔ | ↔ | TG ↔; | NR |”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [227]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“| Loomba et al. | TVB-2640 | NAFLD + fibrosis | PDFF -4.8 % | ↔ | ↔ | TG ↔; | NR |”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [227]
Experimental — accuracy not yet measuredIn the citing paper
“New therapeutic approaches in NASH suggest combination therapies with anti-steatosis, anti-inflammatory, and anti-fibrotic drugs may be effective.68”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [68]
In the citing paper
“As broadly acting drugs NR (eg, FXR) ligands are also explored in combination with anti-diabetic (eg, GLP-1 RA; SGLT2 inhibitors) or anti-inflammatory drugs (eg, CVC) to achieve a higher therapeutic efficacy in NASH which is still in an unsatisfactory range for single agents.236”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [236]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2739 · Cited by 200
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Research works printed but not linked: 3
- Amin, 2019, PF-05221304 (PF’1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in afults with non-alcoholic fatty liver disease demonstrates robust reductions in liver fat and ALT - phase 2a, dose ranging study, Hepatology, 70 Suppl, 21
- 2019, Effects of cotadutide (MEDI0382) on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 26-week analysis of a randomized phase 2B study, Hepatology, 70, 24A
- Press release: Gilead Announces Topline results from phase 2 atlas study in patients with bridging fibrosis (F3) and compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH) 2019.
Cited by
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“Combination therapies, coupled with non-pharmaceutical interventions, are likely to become the cornerstone of treatment for MASH by targeting synergistic pathways and lowering toxicity 335 .”
Self-citationNonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Current treatment of non‐alcoholic fatty liver disease
Paternostro, R., & Trauner, M. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13531 · Cited by 305
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
“Several drug molecules with different mechanisms of action are under development to treat this common and burden-some liver disease, although their efficacy has been limited [18].”
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Metadata
- Authors
- Dufour, J.-F., Caussy, C., & Loomba, R.
- Affiliations
- University of Bern (CH)
- University of California San Diego (US)
- Corresponding author
- Dufour, Jean-François
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2020-05-07
- Volume
- 69
- Issue
- 10
- Pages
- 1877-1884
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC7497577
- OpenAlex
- W3020979243
- Cited by
- 193
- References
- 74
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 31 · 2023: 36 · 2022: 43 · 2021: 38 · 2020: 11
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gut (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Department of Defense (5UL1TR001442, CA170674P2)
- National Institutes of Health (UL1TR001442)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK106419, P30DK120515)
- National Institute of Environmental Health Sciences (P42ES010337)
- National Center for Advancing Translational Sciences
- DOD Peer Reviewed Cancer Research Program
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- nonalcoholic steatohepatitis, combination therapy, NASH treatment, liver cirrhosis, therapeutic target, pathophysiology, drug development, pharmacological interventions
- MeSH terms
- Clinical Trials as Topic, Drug Therapy, Combination, Humans, Treatment Outcome, Medication Therapy Management, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. https://app.cochat.ai/papers/10.1136/gutjnl-2019-319104
- The paper
- Dufour, J.-F., Caussy, C., & Loomba, R. (2020). Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. https://doi.org/10.1136/gutjnl-2019-319104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.